Profiling of matrix metalloproteinases and tissue inhibitors of metalloproteinases proteins in bladder urothelial carcinoma

Chuang,Cheng-Keng; Pang,See-Tong; Chuang,Tai-Jung; Liao,Shuen-Kuei

doi:10.3892/ol_00000121

Profiling of matrix metalloproteinases and tissue inhibitors of metalloproteinases proteins in bladder urothelial carcinoma

Authors:
- Cheng-Keng Chuang
- See-Tong Pang
- Tai-Jung Chuang
- Shuen-Kuei Liao
View Affiliations

Affiliations: Department of Surgery, Division of Uro-Oncology, Chang Gung Memorial Hospital, Chang Gung University, 333 Taiwan, R.O.C. chuang89@cgmh.org.tw
Published online on: July 1, 2010 https://doi.org/10.3892/ol_00000121
Pages: 691-695

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We investigated the matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinase (TIMPs) proteins in transitional cell carcinoma (TCC) cell lines and surgical specimens of the bladder neoplasm. The expression level was correlated to the degree of cellular differentiation and invasiveness of bladder cancer. Panels of six TCC cell lines with different degrees of differentiation were tested with monoclonal antibodies (mAbs) to MMP-1, MMP-2, MMP-3, MMP-9a, MMP-9b, TIMP-1 and TIMP-2 by immunocytochemistry. Gelatin zymography was also conducted on the cell lines for MMP-2 and -9. In addition, immunohistochemistry with the mAbs to MMP and TIM molecules was performed on 30 TCC specimens. We found that TCC cell lines were stained positively for MMP-1 (6/6), weakly for MMP-9a (2/6), MMP9b (5/6) and TIMP-1 (3/6), and negatively for MMP-2 (3/6) and MMP-3 (3/6). Zymographic analysis of the cell lines showed a high level of MMP2 in the MGH-U4 cell line. In bladder cancer surgical specimens, all specimens were positive for MMP1 (30/30), 19 were positive for MMP-2 (63.3%), 21 positive for MMP-9a (70%) and 15 positive for MMP-9b (50%). The expression of MMP-2 was found to be positively correlated with higher-grade tumors (p=0.036) and the expression of MMP-9a and -9b was found to be positively correlated with tumor stage (p=0.012 and 0.023, respectively). However, the expression of MMP-1, MMP-3, TIMP-1 and TIMP-2 was not correlated with either tumor staging or grading. In conclusion, the expression of MMP-2 and -9 was correlated with high-grade or high-stage bladder tumors, respectively. However, this correlation was not observed with TCC cell lines in which high- and low-grade tumors are included. Immunohistochemical results on tumor lesions may have more clinical relevance, since in a given tumor microenvironment the interaction among tumor cells in situ and tumor-associated cells, such as neutrophils, macrophages, lymphocytes and endothelial cells, as well as environmental factors (hypoxia and pH), cytokines and growth factors released by these cells may be required for TCC to express selective MMPs and TIMPs. The selective expression of these molecules then regulates tumor progression.

View Figures

View References

1	Liotta LA: Tumor invasion and metastasis: role of the extracellular matrix. Cancer Res. 46:1–7. 1986.PubMed/NCBI
2	Chuang CK and Liao SK: Differential expression of CD44 variant isoforms by cell lines and tissue specimens of transitional cell carcinoma. Anticancer Res. 23:4635–4640. 2003.PubMed/NCBI
3	Brown PD, Levy AT, Margulies IMK, Liotta LA and Stetler-Stevenson WG: Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res. 50:6184–6191. 1990.PubMed/NCBI
4	Fleshner NE, Herr HW, Stewart AK, Murphy GP, Mettline C and Menck HR: The national cancer data base report on bladder carcinoma. Cancer. 77:1505–1513. 1996. View Article : Google Scholar
5	Chuang CK and Liao SK: Evaluation of CA19-9 as a tumor marker in urothelial malignancy. Scand J Urol Nephrol. 38:359–365. 2004. View Article : Google Scholar : PubMed/NCBI
6	Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 284:67–68. 1980. View Article : Google Scholar : PubMed/NCBI
7	Koivunen E, Ristimaki A, Itkonen O, Osman S, Vuento M and Stenman UH: Tumor-associated trypsin participates in cancer cell mediated defradation of extracellular matrix. Cancer Res. 51:2107–2112. 1991.PubMed/NCBI
8	Van Wart HE and Birkedal-Hansen H: The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA. 87:5578–5582. 1990.PubMed/NCBI
9	Mignatti P and Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev. 73:161–195. 1993.PubMed/NCBI
10	Liu BCS and Liotta LA: Biochemistry of bladder cancer invasion and metastasis: clinical implications. Urol Clin North Am. 19:621–627. 1992.PubMed/NCBI
11	Redwood SM, Liu BCS, Weiss RE, Hodge DE and Droller MJ: Abrogation of the invasion of human bladder tumor cells by using protease inhibitor(s). Cancer. 69:1212–1219. 1992. View Article : Google Scholar : PubMed/NCBI
12	Liotta LA and Stetler-Stevenson WG: Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res. 51:5054–5059. 1991.PubMed/NCBI
13	Agnes N, Maud J and Erik M: Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol. 19:52–60. 2008. View Article : Google Scholar : PubMed/NCBI
14	Kitagawa Y, Kunimi K, Ito H, et al: Expression and tissue localization of membrane-types 1, 2 and 3 matrix metalloproteinases in human urothelial carcinomas. J Urol. 160:1540–1545. 1998. View Article : Google Scholar : PubMed/NCBI
15	Nakajima M, Welch DR, Belloni PN and Nicolson GL: Degradation and basement membrane type IV collagen and lung subendotherial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res. 47:4869–4876. 1987.PubMed/NCBI
16	Nakajima M, Welch DR, Wynn DM, Tsuruo T and Nicolson GL: Serum and plasma Mr 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res. 53:5802–5807. 1993.PubMed/NCBI
17	Pyke C, Ralfkiaer E, Tryggvason K and Dano K: Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol. 142:359–365. 1993.PubMed/NCBI
18	Stearns ME and Wang M: Type IV collagenase (Mr 72,000) expression in human prostate: benign and malignant tissue. Cancer Res. 53:878–883. 1993.PubMed/NCBI
19	Kanayama HO, Yokota KY, Kurokawa Y, Murakami Y, Nishitani M and Kagawa S: Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer. 82:1359–1366. 1998. View Article : Google Scholar : PubMed/NCBI
20	Grignon DJ, Sakr W, Toth M, et al: High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res. 56:1654–1659. 1996.PubMed/NCBI
21	Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
22	Davis B, Waxman J, Wasan H, et al: Levels of matrix metalloproteinase in bladder cancer correlate with tumor grade and invasion. Cancer Res. 53:5365–5369. 1993.PubMed/NCBI
23	Gerhards S, Jung K, Koenig F, et al: Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology. 57:675–679. 2001. View Article : Google Scholar : PubMed/NCBI
24	Cawston TE, Galloway WA, Mercer E, Murphy G and Reynolds JJ: Purification of rabbit bone inhibitor for collagenase. Biochem J. 195:159–165. 1981.PubMed/NCBI
25	Docherty AJ, Lyons A, Smith BJ, et al: Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature. 318:66–69. 1985. View Article : Google Scholar : PubMed/NCBI
26	Mignatti P, Robbins E and Rifkin DB: Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell. 47:487–498. 1986. View Article : Google Scholar : PubMed/NCBI
27	Schultz RM, Silberman S, Persky B, Bajkowski AS and Carmichael DF: Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16–F10 melanoma cells. Cancer Res. 48:5539–5545. 1988.PubMed/NCBI
28	Alvarez OA, Carmichael DF and DeClerck YA: Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhititor of metalloproteinases. J Natl Cancer Inst. 82:589–595. 1990. View Article : Google Scholar : PubMed/NCBI
29	Stetler-Stevenson WG, Krutzsch HC and Liotta LA: TIMP2: identification and characterization of a new member of the metalloproteinases inhibitor family. Matrix Supplement. 1:299–306. 1992.PubMed/NCBI
30	Denhardt DT, Khokha R, Yagel S, Overall CM and Parhar RS: Oncogenic consequences of down-regulating TIMP expression in 3T3 cells with antisense RNA. Matrix Supplement. 1:281–285. 1992.PubMed/NCBI
31	Baker EA, Stephenson TJ, Reed MW and Brown NJ: Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol. 55:300–304. 2002. View Article : Google Scholar : PubMed/NCBI
32	Takahashi K, Eto H and Tanabe KK: Involvement of CD44 in matrix metalloproteinase-2 regulation in human melanoma cells. Int J Cancer. 29:387–395. 1999. View Article : Google Scholar : PubMed/NCBI
33	Isacke CM and Yarwood H: Molecules in focus. The hyaluronan receptor, CD44. Int J Biochem B. 34:718–721. 2002. View Article : Google Scholar